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Abstract
Background: MicroRNAs (miRNAs) are important key regulators in multiple cellular functions, due to their a crucial
role in different physiological processes. MiRNAs are differentially expressed in specific tissues, during specific cell
status, or in different diseases as tumours. RNA sequencing (RNA-seq) is a Next Generation Sequencing (NGS)
method for the analysis of differential gene expression. Using machine learning algorithms, it is possible to
improve the functional significance interpretation of miRNA in the analysis and interpretation of data from RNA-
seq. Furthermore, we tried to identify some patterns of deregulated miRNA in human breast cancer (BC), in order
to give a contribution in the understanding of this type of cancer at the molecular level.
Results: We adopted a biclustering approach, using the Iterative Signature Algorithm (ISA) algorithm, in order to
evaluate miRNA deregulation in the context of miRNA abundance and tissue heterogeneity. These are important
elements to identify miRNAs that would be useful as prognostic and diagnostic markers. Considering a real word
breast cancer dataset, the evaluation of miRNA differential expressions in tumours versus healthy tissues evidenced
12 different miRNA clusters, associated to specific groups of patients. The identified miRNAs were deregulated in
breast tumours compared to healthy controls. Our approach has shown the association between specific sub-class
of tumour samples having the same immuno-histo-chemical and/or histological features. Biclusters have been
validated by means of two online repositories, MetaMirClust database and UCSC Genome Browser, and using
another biclustering algorithm.
Conclusions: The obtained results with biclustering algorithm aimed first of all to give a contribute in the
differential expression analysis in a cohort of BC patients and secondly to support the potential role that these
non-coding RNA molecules could play in the clinical practice, in terms of prognosis, evolution of tumour and
treatment response.
Background
MicroRNAs (miRNAs), among small non coding RNAs
(sncRNAs), are emerging as key regulators in multiple
cellular functions, due to their crucial role in many
important physiological processes (cell development, cell
proliferation, apoptotic process, and response to different
external and stress signals) [1]. Moreover it has been
recently demonstrated that miRNAs are differentially
expressed in specific tissues, during specific cell statuses,
or in many diseases as tumours [2]. MiRNAs are small
non coding molecules of single stranded RNA, 22-25 nt
long, involved in the negative regulation of the gene
expression to a post-transcriptional level. MiR-NAs in
fact pair with specific RNA messengers (mRNA), causing
their degradation or blocking the translational process of
the protein product [3-5]. An interesting application
involving these elements is the analysis of differential
gene expression, obtained by comparing the transcrip-
tional profiles of two or more individuals, tissues or cell
types. Massive sequencing technique is an increasingly
popular method used to study this mechanism. For
instance, information on transcripts in healthy and
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diseased subjects may allow to identify which genes are
expressed in a significantly different manner between
these two groups and, thus, it is used to highlight differ-
ences that involve the pathological condition. Based on
the evidence that groups of miRNAs are differentially
expressed in several types of cancer, it is possible to
study their involvement, negatively or positively, in the
control of intracellular signalling pathways that have a
direct influence on cancerous growth, such as prolifera-
tion and apoptosis. Therefore those miRNAs could act as
oncogenes or tumour suppressors [3,6-11]. The impor-
tance of miRNAs in the regulation of gene expression is
underlined also by the fact that few miRNAs can interact
on many mRNAs. The altered expression of a single
miRNA can lead to the deregulation of several molecular
pathways, that may contribute separately, or cooperate,
to the emergence of a malignant cell phenotype [1,12,13].
Many scientific works about differential gene expression
analysis, show an association of miRNAs with develop-
ment and tumour progression, as chronic lymphocytic
leukemia (CLL), prostate cancer, non-small cell lung can-
cer (NSCLC), colorectal cancer (CRC) [2,7,14-17]. Voli-
nia et al [18], reported a microarray analysis of miRNAs
on 540 samples belonging to different tumour types
(lung, breast, stomach, prostate, colon, pancreas), and
showed a miRNA signature that join different solid
tumours. Inside this signature were found miRNAs
already known to be associated with other cancers,
among them miR-17-5p, miR-20a, miR-21, miR-92, miR-
106a, and miR-155. In this last decade more than 400
studies focusing on the role of miRNA expression levels
and their regulation in breast cancer have been published
[19]. Unfortunately, most of these studies were focused
only on a specific subset of miRNAs, or a limited group
of patients [20,21]. The role of microRNAs was also
demonstrated in the early stages of the disease progres-
sion and metastasis. In fact, several experimental evi-
dences showed the involvement of miRNAs in the
regulation of biological processes that lead to the acquisi-
tion of metastatic potential, including adhesion, invasion,
migration, epithelial-mesenchymal transition (EMT) and
angiogenesis [22,23].
In the past decade, the microarray technique was suc-
cessfully used for the analysis of gene expression but,
due to some limitations [24-26], more recently microar-
ray technology was accompanied by RNA sequencing
(RNA-seq) method for the analysis of the transcripts.
RNA-seq method belongs to Next Generation Sequen-
cing (NGS) techniques and generates DNA sequences
complementary to the RNA reference molecule. With
respect to microarray, two main advantages of RNA-seq
method are (1) the ability to quantify a large dynamic
range of expression levels, with absolute rather than
relative values, and (2) the absence of a priori knowledge
of the sequence to be analysed [27].
Nevertheless, there is not a standard method used to
analyse the gene expression by RNA-seq data. In order
to assist biologists in the complex task of interpretation
of the large amount of data produced by NGS techni-
ques, an investigation technique should be based on
computational methods.
Clustering methods have been usually used to analyse
gene expression data, with the purpose to discover
groups of genes (clusters) that are co-regulated with
respect to certain experimental conditions. Traditional
clustering approaches, like for instance k-means algo-
rithm, however, have proved to perform well only with
a small set of expression data. With large datasets, com-
posed of thousands of genes and hundreds of experi-
mental conditions, clustering techniques are not able to
correct identify the gene clusters, because they consider
the expression profiles under all conditions at the same
time. Many regulation mechanisms, indeed, involve only
a set of genes and a limited set of experimental condi-
tions [28,29]. For this reason, in recent years biclustering
algorithms have been developed for the study of gene
expression data [30]. A bicluster is defined as a group of
genes showing a similar regulation behaviour over a
subset of experimental conditions. Moreover biclustering
allows to obtain overlapping biclusters, in which a gene
can be involved in different regulation patterns accord-
ing to the groups of considered conditions. The biclus-
tering approach can contribute to interpret the big
amount of RNA-seq data in an easier, faster and specific
way. Moreover, as reported by literature, miRNAs are
deregulated in breast cancer as well as in other hemato-
poietic and solid tumours [2,6,14,19,20,23]. Clustering
those molecules according to subclass of tumours by
histological and molecular point of view can help to bet-
ter define a potential role of miRNA as prognostic, diag-
nostic and therapeutic markers.
The use of biclustering algorithm in order to correlate
miRNA profiles to specific tumour features was sup-
ported by a recent work [31]. It showed the use of a
biclustering approach to detect breast cancer subgroups
with common clinical features. The proposed approach
can be a new useful method to analyse and stratify
treatment and predict prognosis, with respect to not
fixed sets of genomic biomarkers.
The present work, that is an extended version of [32],
will take into account miRNA expression profiles in
breast cancer samples and healthy controls, in order to
identify some patterns of deregulated miRNA in human
breast cancer and to give a contribution in the under-
standing of the mechanism involved in the regulation of
this type of cancer.
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Methods
Biclustering is a computational procedure that separates
homogeneous sub-matrices inside a matrix composed of
objects vs features. In our study the data matrix is con-
stituted by samples vs miRNAs. The biclustering proce-
dure selects simultaneously a subset of features that
characterizes a subset of samples, on the basis of a
“local similarity” criterion. On the contrary, traditional
clustering groups together objects that are similar with
respect to the whole set of features, not to a subset of
features [30]. It is also clear that a proper biclustering
technique is also different from a two-steps clustering
that acts first on rows and then on columns of the data
matrix, such as the double hierarchical clustering imple-
mented in [33]. Considering our study, biclustering will
find a subset of miRNAs that are differentially expressed
with regards to a subset of samples. Among the available
biclustering tools, we consider the Iterative Signature
Algorithm (ISA) [34].
Figure 1 shows the whole pipeline used in this work.
The input is a matrix of miRNA expression profiles,
preprocessed using a standard distribution normaliza-
tion, as recommended by ISA’s authors. Then ISA algo-
rithm is executed and the resulting biclustering (miRNA
clusters vs patients) is represented with a heatmap
visualization. Finally, there is the three steps validation
of each bicluster, using the MetaMirClust online reposi-
tory [35], the analysis of literature collected in UCSC
Genome browser [36] and the consensus of our results
by means of another biclustering technique, the SAMBA
algorithm [37].
Iterative signature algorithm
According to recent surveys [38,39] that compare sev-
eral biclustering algorithms on gene expression datasets,
the ISA algorithm [34] is one of the most effective.
Given a gene expression matrix, ISA algorithm discovers
simultaneously sets of coregulated genes and the corre-
sponding sets of experimental conditions. These biclus-
ters are called transcription modules by ISA’s authors.
In our approach, the set of genes are represented by a
set of miRNAs and the experimental conditions can be
identified with breast cancer samples and healthy
tissues.
Considering a gene expression matrix E of size m × n
(with m = number of genes and n = number of sam-
ples), the ISA algorithm works in the following way.
First of all, it is created a random sparse 0/1 vector of
size m, called seed vector r0. The elements of r0 are
used to select a subset of the genes (rows). E is then
transposed (E’), it is multiplied by r0, and the result is
thresholded, obtaining as result the vector c0 of size n.
This threshold is obtained computing the mean and
standard deviations of the vector c0, and considering
only the elements that have a standard deviation from
the mean higher than the threshold. The vector c0 is
then used to select a subset of the input samples, con-
sidering only the columns of E corresponding to the
non-zero components of c0. After that, E is then multi-
plied by c0, and the result is again thresholded in order
to obtain the vector r1 (of size m). This procedure is
iteratively repeated until either ri-1 and ri, and ci-1 and ci
are close enough, according to a convergence criteria
Figure 1 The proposed pipeline. Starting from miRNA count, we apply a normalization of data and perform a biclustering with ISA algorithm.
The supervised evaluation exploits two online repositories, MetaMirClust and UCSC Genome browser, and validation by consensus with SAMBA
algorithm.
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defined in terms of Pearson correlation. The final vec-
tors rfinal and cfinal are used to extract a subset of
the genes and samples, composing the biclusters, from
the expression matrix E. Genes are selected considering
the rows of E corresponding to the the non-zero com-
ponents of rfinal; samples are selected considering the
columns of E corresponding to the the non-zero compo-
nents of cfinal. Therefore the two most important para-
meters of ISA algorithm are the two thresholds: thr for
the matrix rows (representing the genes), thc for the
matrix columns (associated to the samples). The thresh-
old values affect the composition of the biclusters: for
example, if the row (gene) threshold is high, then the
biclusters will have very similar genes. Lower threshold
values, in turn, will provide bigger biclusters with less
similar genes. The same behaviour applies when consid-
ering the column (sample) threshold. Moreover the
biclusters are “soft”, meaning that they allow overlap-
ping among genes and/or samples, and, according to the
threshold values, it is possible that groups of genes and
samples do not belong to any bicluster. It is also possi-
ble to obtain a bicluster that correlates a single gene
with a group of patients and vice versa. As the authors
state, ISA algorithm has the best performance proces-
sing normalized input data, i.e the input matrix have
zero mean and standard deviation equal to one. In addi-
tion to the biclusters, ISA algorithm also provides as
output two numeric matrices: one for the row (gene)
components of the bicluster, and another one for the
column (sample) components of the bicluster. Consider-
ing for example the resulting matrix for the genes, each
column corresponds to a bicluster. The rows with a
non-zero value belong to the bicluster related to that
column. These matrices have values ranging from -1
and +1 and they express the association degree of a
gene, or sample, to that bicluster. If two genes belong to
the same bicluster with the same sign, they are corre-
lated, otherwise they are anti-correlated. In the following
discussions, for sake of simplicity, we take into account
the output matrix having samples as rows, and the
miRNA biclusters as column. Since the biclusters are
unique, the same conclusions hold when considering
miRNA vs sample biclusters.
In our work, we used the ISA implementation pro-
vided by the R package isa2 [40].
Validation technique
We adopted two different validation criteria: 1) semi-
supervised evaluation criterion, based on scientific litera-
ture; 2) consensus with another biclustering tool, the
SAMBA algorithm [37], that has proven to discover
relevant subsets of genes and samples from gene expres-
sion data [41]. Indeed, since we cannot perform in vitro
experiments, we referred to: 1) an external repositories
providing informations about different groups of miR-
NAs in human species; 2) a different biclustering algo-
rithm to compare our results with.
In particular, we investigated over MetaMirClust data-
base [35] and UCSC Genome browser [36]. The former
is a repository of miRNAs in animalia kingdom that pro-
vides a useful bioinformatics resource to facilitate the
advanced interrogations on the composition of miRNA
clusters. The latter is a genome browser containing a col-
lection of annotation for several genomic regions and, for
each annotation, it reports its description, details about
its construction, methods used in the experimentation,
validation, credits, and references. Exploiting these two
services, we could compare miRNA clusters obtained by
the proposed technique with those contained in Meta-
MirClust and then we found for each bicluster all avail-
able literature references in UCSC Genome browser.
Finally, we got information from references, in order to
examine how they are related to differential expression of
miRNAs in breast cancer. Our biclustering results were
further validated using the SAMBA biclustering algo-
rithm by checking if it is able to discover the same biclus-
ters obtained through the ISA algorithm.
Results and discussion
In this section, we introduce the experimental dataset
and then we discuss the biclustering results obtained
according to the proposed pipeline, introduced in the
Section Methods.
Experimental dataset
We used a breast cancer dataset composed of a large
cohort of patients. RNA-seq data were collected by Far-
azi et al ([33]) and uploaded in Sequence Reads Archive
data bank (SRA, http://www.ncbi.nlm.nih.gov/Traces/
sra/sra.cgi). The miRNA expression profiles were down-
loaded from Gene Expression Omnibus (GEO) with
accession number GSE28884. The dataset is composed
of 169 tumour samples, 10 healthy tissues, 6 cell lines
(MCF7, MCF10A, HCC38, BT474, MDA-MB134, and
ZR-751), for a total of 185 samples. We wanted, indeed,
to test the efficacy of the ISA biclustering algorithm on
a real dataset, not altered by a guided choice of the sam-
ples, and on a real life problem as the breast cancer ana-
lysis. Another parameter that we took into account was
the partition of samples according to the clinical and
histo-pathological features, molecular sub-type and the
presence of one or more immune-histo-chemical (IHC)
markers (ER, PR, Her2 status). Our aim is in fact to dis-
cover relationships between specific patterns of patients
and specific groups of miRNA.
Our biclustering approach allowed us to evaluate
miRNA deregulation in the context of miRNA abun-
dance, and tissue heterogeneity, important elements in
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identifying miRNAs that would be useful prognostic and
diagnostic markers.
Figure 2 shows the dataset composition. In order to ver-
ify if there could be some potential link between miRNA
biclusters and some specific tumour characteristic, we
considered three features (the list of patient features was
provided by Farazi et al. [33]): a) presence or absence of
IHC markers; b) clinical and histo-pathological features; c)
molecular sub-type. For the IHC markers, point (a), it was
considered the presence or absence in a tumour sample of
Estrogen Receptor (ER), Progesteron Receptor (PR), or the
ERB2/Her2 protein. As it can be seen the majority of
patients are triple negative (46%). From a molecular point
of view these patients could be relevant to deeper under-
stand the biology of these tumours and potentially to give
answers in terms of pharmacological treatments. Regard-
ing the clinical and histopathological features, point (b),
patients are divided in IDC (Invasive Ductal) (68%), DCIS
(Ductal carcinoma In Situ) (9%), Normal samples (healthy
controls) (6%), Metaplastic (5%), Cell lines (3%) and others
(atypical medullary, apocrine, adenoid, mucinous A). It
can be noticed that also this feature is non-homogeneous
as the most part of analysed samples are IDC, compared
to all the other tumour samples and healthy controls. The
third characteristic, point (c) that we considered was the
molecular sub-type, shared in basal (42%), Luminal A
(13%), Her2 (12%), Normal (11%), Luminal B (3%) and
19% of remaining samples were NA, because we did not
have information regarding their molecular sub-type.
Regarding the miRNA profiles, we set the threshold
for sample comparison to 5,000 total miRNA sequence
reads per replicate merged library, as reported in [33],
identifying 231 miRNA. miRNA profiles of a sample
have been presented as relative percent (%) miRNA read
frequencies (rf) by dividing miRNA read counts by total
miRNA reads per library. Furthermore, miRNA profiles
have been condensed by assigning individual miRNA to
sequence families (denoted by sf-miR). This approach
reduces the complexity of the data. The sequence
families are most informative for characterization of
seed-sequence-dependent miRNA-target regulation. We
considered the miRNA families as identified in the work
of Farazi et al. [33] and provided in the Supplementary
Table S4 available from the supplementary material of
their work.
Experimental results
We aimed to evaluate the differential expression of miR-
NAs in breast cancer samples versus healthy tissues.
Figure 3 shows the results obtained by the ISA algo-
rithm. Membership values, ranging from -1 to +1, are
showed for every patient and each miRNA bicluster, as
produced by the ISA algorithm. Starting from the heat-
map visualisation, we considered the patients belonging
to the miRNA bicluster with the highest membership
value. The differential expression analysis evidenced 12
different miRNA clusters. Each of these was associated
to a specific cluster of patients. Figure 4 summarizes the
composition of each bicluster, their references in scienti-
fic literature and if they were also discovered by the
SAMBA algorithm, as explained in Section Validation
Technique. Since the analysis of all the biclustering
results obtained through SAMBA algorithm is not in
the scope of this work, we provide them in the Supple-
mentary Material, Additional file 1 and 2, for sake of
completeness.
The two thresholds of the ISA algorithm were regu-
lated in order to have a manageable (not too large) and
meaningful number of biclusters. thr was set equal to
3.5, thc was set equal to 1.0. Other threshold values gave
Figure 2 Dataset Composition. The real world dataset is composed by 185 samples. Each pie represents a different characteristic, where the
percentage values give information about the composition of the dataset.
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Figure 3 Bicluster visualization. The heatmap shows the membership of each patient with regards to the 12 miRNA biclusters. Only the
patients belonging to at least one miRNA bicluster are reported. Membership ranges from -1 to +1, with 0 meaning no membership. +1 and -1
indicate highest membership, but with opposite correlation degree. The heatmap indicates a strong relationship between some features of the
dataset and specific subclass of miRNA. Indeed the expression patterns of miRNA family hsa-mir-17/19a/17*/20a* inside the azure rectangle
shows an almost exclusive link with TNBC samples. The pink rectangle in miRNA-205 links this non coding RNA to a specific subclass of BC
samples. The blue rectangle evidences an inverse correlation between the mir-452 and some IDC samples. The grey rectangle evidences the
association to mir-320-RNASEN(1) with histological normal samples
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Figure 4 Table of biclustering results. It reports, for each obtained bicluster, the group of miRNAs and the number of patients. In addition, for
each patient in bicluster, some main characteristics are reported. The last two columns contain references provided by literature works and the
number of the related bicluster, if any, discovered by the SAMBA algorithm. All the biclusters obtained with SAMBA algorithm are provided in
the Supplementary material, Additional file 1 and 2. See caption of Figure 3 for details about red, blue, azure and green rectangles.
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few clusters but with many elements, or many clusters
with few elements. Considering the random initialization
of ISA algorithm we ran it ten times with different initi-
alization values but with the same thresholds, in order
to assess the stability of the 12 biclusters. Each time we
obtained the same 12 biclusters, although with a differ-
ent sorting. As it is evident in Figure 4, 7 out of 12
biclusters are composed of one sequence family. Unli-
kely traditional clustering methods, where a cluster with
only one element has often very low importance, a
bicluster that correlates a single element with a group of
features give us a lot of information.
As it will be discussed in the rest of this section,
indeed, biclusters composed of one single miRNA family
linked to a group of samples, enable us to associate a
particular miRNA family to a set of sample tissues with
well defined immuno-histochemical and histological fea-
tures. This characteristic of the algorithm allows in a
“one step” process to obtain results that are normally
produced with more passages with a classical hierarchi-
cal clustering process.
Our biclustering procedure highlighted many results
from the original work of Farazi et al [33], it also pro-
duced other results that are confirmed by other works
in the literature, and some new results that need more
investigation. First of all we comment the results in
accordance with the original Farazi work.
The first step of our analysis was to check if the
healthy tissues were univocally associated to the same
sub-class of miRNA. The data showed an exclusive asso-
ciation between these samples and the miRNA cluster
sf-hsa-miR-320-RNASEN (green rectangle on Figure 3
and Figure 4). The obtained data were confirmed by
Farazi et al. [33] and by the SAMBA algorithm (biclus-
ter 2, available in the supplementary material, Additional
file 1). Moreover, as it will be argued, the algorithm
showed the association between specific sub-class of
tumour samples having the same immuno-histo-chemi-
cal (IHC) and/or histological features and miRNA clus-
ters, as can be evidenced for “atypical medullary” and
DCIS samples that are linked to sf-hsa-miR-148a* and
sf-hsa-miR-148a clusters. The bicluster evidenced also
an over-expression of sf-hsa-miR-142-5p in Her2+/IDC
samples compared to other classes of tumour samples,
as DCIS or TNBC, and compared to healthy controls.
These results were in accordance with the evidence
reported by Farazi et al [33]. SAMBA biclustering
showed an association between this miRNA bicluster,
ER+/PR+/IDC, and HER2+/IDC samples, confirming
our results. Indeed there is an over-expression of this
group of microRNA with regards to these classes of
samples. Moreover the algorithm reported a down-
expression of TNBC samples for this miRNA cluster
(supplementary material, Additional file 1 bicluster 10).
Some IDC samples have shown an association to
miRNA sf-hsa-miR-199a-1-3p, sf-hsa-miR199a-1-5p e
sf-hsa-miR-214-3p clusters, that were over-expressed.
Schwarzenbach et al. and Shatseva et al. confirmed our
data clustering, showing increased levels of mir-214 in
serum of BC patients compared to healthy controls
[42,43]. The analysis with SAMBA algorithm reported
also an over-expression for ER+/PR+/IDC, Her2+/IDC
samples, confirming our results; it also reported a
down-expression for some TNBC samples not evidenced
with ISA biclustering (supplementary material, Addi-
tional file 1 bicluster 9).
Triple Negative Breast Cancer samples (TNBC) are a
distinct group of tumour samples characterized from
distinct histological and IHC features, as they lack for
the presence of estrogen receptor (ER), progesterone
receptor (PR), and Her2 protein receptors. They are
associated to a specific pattern of miRNA, that is disre-
gulated: sf-hsa-miR-17, sf-hsa-miR-19a, sf-hsa-miR-17*,
and sf-hsa-miR-20a* (azure rectangle on Figure 3 and
Figure 4). These are oncogenes and their targets are
“tumour suppressors” of the cell cycle. Many scientific
works report an over-expression of this cluster of
miRNA in different types of solid tumours and hemato-
poietic diseases [33,44]. Especially, this association
involves a specific sub-class of TNBC that is the “basal
like subtype”, as reported also by De Rinaldis et al. [45].
This evidence suggests the tendency of specific miRNA
that are “sub-type specific” to influence the expression
levels of their targets. The identification of a cluster of
miRNA specifically linked to the TNBC sub-class of
samples is very important because nowadays there are
not targeted therapies for this BC sub-class. The discov-
ery of miRNAs associated with TNBC could mean to
find a less invasive strategy of intervention. Differently
from our results, SAMBA biclustering reported a down-
expression for miR-17* and miR-20* in TNBC samples
(supplementary material, Additional file 1 bicluster 7).
In literature, data about the role of miRNA-205 are
conflicting: our biclustering approach highlighted an
over-expression of this miRNA in some IDC, adenoid
and metaplastic samples (pink rectangle on Figure 3 and
Figure 4). Interestingly, a closer look to the IHC features
evidenced that this specific class of miRNA strongly
associates to TNBC samples, as the values reported by
the algorithm are almost equal to 1 in absolute value.
This data was in accordance with the result obtained by
Farazi et al. [33]. No association was found for this
bicluster with SAMBA analysis. Other miRNA profiling
has shown increased levels of this miRNA-205 in BC
samples without vascular invasion compared to those
with vascular invasion. Moreover miR-205 has been
shown to be down-regulated in BC tumour samples and
BC cellular lines [46,47].
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miR-423-3p and miR-423-5p are the mature tran-
scripts of miR-423. Many scientific works reported that
their expression was altered in different forms of cancer
type [33,48-50]. Farazi et al. reported that these two the
mature forms of miR-423 were highly expressed in duc-
tal infiltrating BC that subsequently give metastasis,
underlying the prognostic independent role of the dis-
ease [33]. Our biclustering analysis evidenced a distinct
group of IDC patients where miR-423 was over-
expressed. SAMBA biclustering showed an association
with only miR-423-5p and some distinct groups of sam-
ples: an over-expression was associated to Her2+/IDC
samples, and a down-expression was found with ER
+/PR+/mucinous A samples (supplementary material,
Additional file 1 bicluster 6).
The proposed biclustering procedure gave some new
results discussed below; many of these findings are con-
firmed by other papers in the literature. As general
observation we found that most of the results are related
to over-expressed miRNAs, with only one bicluster (row
10 in Figure 4) involving down-regulated miRNAs.
The differential expression analysis of sf-hsa-miR-103-
1 showed an over-expression in IDC cluster samples,
positive for at least one of three IHC marker (PR/ER/
Her2). These results have been confirmed by SAMBA
biclustering (supplementary material, Additional file 1
bicluster 4). A recent work of Wang X. evidenced a
potential role of this microRNA as serum biomarker in
BC patients. Moreover its expression correlates with an
advanced state of the disease (P < 0.05) and with linfo-
nodal metastasis (P < 0.05) [51].
The sf-hsa-miR-452 is involved in different processes
as cell-cell interaction, cell growth and proliferation,
inflammatory response and apoptotic processes. The
biclustering algorithm showed a strong down-expression
of this miRNA family (blue rectangle on Figure 3 and
Figure 4). Interestingly Van Schooneveld et al. [52]
referred an over-expression in healthy patients com-
pared to BC patients, and they evidenced a positive
association (P < 0.05) between expression levels of miR-
452 in serum of patients and the number of methylated
genes in plasma. The experimental evidences showed a
strong over-expression of miR-452 in healthy controls
compared to tumour samples, and because of the evi-
dence of the stability of this miRNA in plasma, the
authors speculated a potential role as biomarker for the
detection of BC in human plasma. SAMBA biclustering
reported no association for this miRNA.
The biclustering analysis showed an over-expression of
sf-hsa-miR-193a-3p in IDC sub-class of patients. An
over-expression of this miRNA in tumour samples was
previously evidenced in other works as reported by
Fung Lin Yong [53]. No association was found with
SAMBA algorithm.
Our algorithm produced also some results that are
often discordant from literature: miR-141 and miR-200c
belong to a miRNA family of important regulator of cel-
lular transition from epithelial to mesenchymal (EMT)
[54-56]. Moreover, miR-200c has been shown to play a
role in disregulation of normal expression patterns of
different cancer types [18,57]. Our analysis evidenced an
over-expression of sf-hsa-miR-141 in tumour samples
compared to healthy controls. Most of them are IDC,
and Her2 negatives. In literature data are contrasting
[58,59]. Moreover SAMBA biclustering reported no
results for this miRNA bicluster.
As previously said, sf-hsa-miR-148a* and sf-hsa-miR-
148a miRNA clusters were linked by the algorithm analy-
sis to “atypical medullary” and DCIS samples. Also these
data differ from literature: scientific works conducted on
different cancer types showed a down-regulation in
tumour samples compared with healthy controls [60-62].
No association was found with SAMBA biclustering.
A new association is reported about the miRNA
bicluster composed of sf-hsa-miR-451-DICER1, sf-hsa-
miR-144, sf-hsa-miR-486: our biclustering showed an
over-expression of this bicluster in a sub-class of IDC/
her2 positive patients. In literature there are no data
regarding an association about this last miRNA bicluster
and breast cancer but there are more evidence about an
over-expression of miRNA 451 in BC and other tumour
samples [63,64]. Instead in [33] it is reported that miR-
144 and miR-451 clustered together but were abundant
in normal breast and reduced in IDC. Interestingly
SAMBA algorithm also reported the association among
miR-451-DICER1, miR-144 and miR-486. For this
miRNA bicluster was evidenced an over-expression in
ER+/PR+ samples (supplementary material, Additional
file 1 cluster 1).
Conclusions
In this paper we used a biclustering approach, by means
of the ISA algorithm, in order to analyse the differential
expression of miRNA in breast cancer samples. Thanks
to its features, the biclustering method allows to cluster
subset of patients with subset of miRNAs, exploiting this
way miRNA biclusters under different samples condi-
tions. Our analysis highlighted 12 miRNA biclusters,
each of them involving different types of tumour samples,
characterized by immuno-histo-chemical, histopathologi-
cal and molecular sub-type features. Biclusters were vali-
dated in the current scientific literature with the support
of the MetaMirClust and UCSC Genome Browser online
tools. Further validation was provided by the consensus
with another biclustering tool, the SAMBA algorithm.
The proposed biclustering methodology has proved a
valid instrument for the study of miRNA expression pro-
files, with the possibility to identify biclusters that can
Fiannaca et al. BMC Bioinformatics 2015, 16(Suppl 4):S7
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provide novel relationships among groups of miRNAs
and patient conditions. Of course, discordant or new
results need to be deeply investigated.
Additional material
Additional file 1: SAMBA biclustering results. Excel file summarizing
the whole biclustering results obtained with SAMBA algorithm. Each
sheet of the file reports the composition, in terms of miRNA and sample,
of each bicluster.
Additional file 2: Bicluster heathmaps. An archive containing the
heatmaps of each bicluster obtained with SAMBA algorithm.
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